ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
24 juil. 2024 10h00 HE
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
24 juil. 2024 08h05 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
22 juil. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
18 juil. 2024 10h20 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces presentation of a TEASE-3 study update showing progression stalled in early-stage Stargardt disease
萬聯行在香港獲得Targretin®️（Bexarotene）用於皮膚T細胞淋巴瘤的上市批准
16 juil. 2024 02h54 HE
|
MAIN LIFE CORPORATION LIMITED
香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...
万联行获得Targretin®（Bexarotene 贝沙罗汀）在香港用于皮肤T细胞淋巴瘤的市场批准
16 juil. 2024 02h54 HE
|
MAIN LIFE CORPORATION LIMITED
香港和澳门的批准标志着Targretin®首次在中国上市贝沙罗汀代表国际临床实践中对复发性皮肤T细胞淋巴瘤(CTCL)的标准治疗 香港, July 16, 2024 (GLOBE NEWSWIRE) -- 万联行有限公司（“Main Life”）今天宣布Targretin®（贝沙罗汀）胶囊在香港获得上市许可，用于治疗至少一次系统治疗无效的皮肤T细胞淋巴瘤 （Cutaneous T-cell...
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma
16 juil. 2024 02h54 HE
|
MAIN LIFE CORPORATION LIMITED
Targretin® (Bexarotene) received Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma.
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
09 juil. 2024 09h00 HE
|
Zevra Therapeutics
CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
09 juil. 2024 05h30 HE
|
ANEW MEDICAL, INC.
ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
27 juin 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has...